This valve may be great for mankind. However, it resides on the "tissue" side of CRY's product line. The margins there are low. Right now 51% of revenues come from tissue related sales. After the allocation of all fixed and variable costs the entire tissue business only generates less that $2 million in free cash flow. The remaining $15 million comes from BioGlue and HemoStase. Those are my WAG calculations anyway.
I will believe its a big deal when it is FDA approved and more importantly when CRY shows me the free cash flow.